drugset / Trial / NCT03121586
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
Timeline
- Start
- 2017-01
- Primary completion
- 2024-04-30
- Completion
- 2024-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimavanserin | Small molecule | 10 mg | Oral |
| Subject | Pimavanserin | Small molecule | 20 mg | Oral |
| Subject | Pimavanserin | Small molecule | 34 mg | Oral |